The impact on hospital resource utilisation of treatment of hepatic encephalopathy with rifaximin-α
Background & Aims Rifaximin‐α reduces the risk of recurrence of overt hepatic encephalopathy. However, there remain concerns regarding the financial cost of the drug. We aimed to study the impact of treatment with rifaximin‐α on healthcare resource utilisation using data from seven UK liver trea...
Gespeichert in:
| Veröffentlicht in: | Liver international 2016-09, Vol.36 (9), p.1295-1303 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 1303 |
|---|---|
| container_issue | 9 |
| container_start_page | 1295 |
| container_title | Liver international |
| container_volume | 36 |
| creator | Orr, James G. Currie, Craig J. Berni, Ellen Goel, Anurag Moriarty, Kieran J. Sinha, Ashish Gordon, Fiona Dethier, Anne Dillon, John F. Clark, Katie Richardson, Paul Middleton, Paul Patel, Vishal Shawcross, Debbie Preedy, Helen Aspinall, Richard J. Hudson, Mark |
| description | Background & Aims
Rifaximin‐α reduces the risk of recurrence of overt hepatic encephalopathy. However, there remain concerns regarding the financial cost of the drug. We aimed to study the impact of treatment with rifaximin‐α on healthcare resource utilisation using data from seven UK liver treatment centres.
Methods
All seven centres agreed a standardised data set and data characterising clinical, demographic and emergency hospital admissions were collected retrospectively for the time periods 3, 6 and 12 months before and following initiation of rifaximin‐α. Admission rates and hospital length of stay before and during therapy were compared. Costs of admissions and drug acquisition were estimated using published sources. Multivariate analyses were carried out to assess the relative impact of various factors on hospital length of stay.
Results
Data were available from 326 patients. Following the commencement of rifaximin, the total hospital length of stay reduced by an estimated 31–53%, equating to a reduction in inpatient costs of between £4858 and £6607 per year. Taking into account drug costs of £3379 for 1‐year treatment with rifaximin‐α, there was an estimated annual mean saving of £1480–£3228 per patient.
Conclusions
Initiation of treatment with rifaximin‐α was associated with a marked reduction in the number of hospital admissions and hospital length of stay. These data suggest that treatment of patients with rifaximin‐α for hepatic encephalopathy was generally cost saving.
See Editorial on Page 1252 |
| doi_str_mv | 10.1111/liv.13111 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1810866318</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1810866318</sourcerecordid><originalsourceid>FETCH-LOGICAL-c3981-f855eb6ce88ad67c6c9f9819f9e9d23ebe55a7b14e4119de868a3664846b6e8e3</originalsourceid><addsrcrecordid>eNp1kLlOxDAQhi0EYrkKXgC5hCIQx4njlAhxSSvOhS0tx5kohlzYDrCPxYvwTBj26Jhizm_-4kdon4THxMdJrd-PCfXdGtoiccoDGlGyvuojOkLb1r6EIcmyhGyiUcSyJEwZ20LFpAKsm14qh7sWV53ttZM1NmC7wSjAg9O1ttJpf-1K7AxI10DrfocKen9QGFoFfSXrzo_VDH9oV2GjS_mpG90G31-7aKOUtYW9Rd1BTxfnk7OrYHx7eX12Og4UzTgJSp4kkDMFnMuCpYqprPR7nyArIgo5JIlMcxJDTEhWAGdcUsZiHrOcAQe6gw7nur3p3gawTjTaKqhr2UI3WEE4CTljlHCPHs1RZTprDZSiN7qRZiZIKH5NFd5U8WeqZw8WskPeQLEily564GQOfOgaZv8rifH181IymH9o6-Bz9SHNq2ApTRMxvbkUd9P76eNN9CDu6A9JsJK_</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1810866318</pqid></control><display><type>article</type><title>The impact on hospital resource utilisation of treatment of hepatic encephalopathy with rifaximin-α</title><source>MEDLINE</source><source>Wiley Journals</source><creator>Orr, James G. ; Currie, Craig J. ; Berni, Ellen ; Goel, Anurag ; Moriarty, Kieran J. ; Sinha, Ashish ; Gordon, Fiona ; Dethier, Anne ; Dillon, John F. ; Clark, Katie ; Richardson, Paul ; Middleton, Paul ; Patel, Vishal ; Shawcross, Debbie ; Preedy, Helen ; Aspinall, Richard J. ; Hudson, Mark</creator><creatorcontrib>Orr, James G. ; Currie, Craig J. ; Berni, Ellen ; Goel, Anurag ; Moriarty, Kieran J. ; Sinha, Ashish ; Gordon, Fiona ; Dethier, Anne ; Dillon, John F. ; Clark, Katie ; Richardson, Paul ; Middleton, Paul ; Patel, Vishal ; Shawcross, Debbie ; Preedy, Helen ; Aspinall, Richard J. ; Hudson, Mark</creatorcontrib><description>Background & Aims
Rifaximin‐α reduces the risk of recurrence of overt hepatic encephalopathy. However, there remain concerns regarding the financial cost of the drug. We aimed to study the impact of treatment with rifaximin‐α on healthcare resource utilisation using data from seven UK liver treatment centres.
Methods
All seven centres agreed a standardised data set and data characterising clinical, demographic and emergency hospital admissions were collected retrospectively for the time periods 3, 6 and 12 months before and following initiation of rifaximin‐α. Admission rates and hospital length of stay before and during therapy were compared. Costs of admissions and drug acquisition were estimated using published sources. Multivariate analyses were carried out to assess the relative impact of various factors on hospital length of stay.
Results
Data were available from 326 patients. Following the commencement of rifaximin, the total hospital length of stay reduced by an estimated 31–53%, equating to a reduction in inpatient costs of between £4858 and £6607 per year. Taking into account drug costs of £3379 for 1‐year treatment with rifaximin‐α, there was an estimated annual mean saving of £1480–£3228 per patient.
Conclusions
Initiation of treatment with rifaximin‐α was associated with a marked reduction in the number of hospital admissions and hospital length of stay. These data suggest that treatment of patients with rifaximin‐α for hepatic encephalopathy was generally cost saving.
See Editorial on Page 1252</description><identifier>ISSN: 1478-3223</identifier><identifier>EISSN: 1478-3231</identifier><identifier>DOI: 10.1111/liv.13111</identifier><identifier>PMID: 26950766</identifier><language>eng</language><publisher>United States: Blackwell Publishing Ltd</publisher><subject>Aged ; cirrhosis ; Cost Savings ; Drug Costs ; Female ; Health Care Costs ; health economics ; Health Resources - statistics & numerical data ; hepatic encephalopathy ; Hepatic Encephalopathy - drug therapy ; Hospitals ; Humans ; Length of Stay - statistics & numerical data ; Liver Cirrhosis - complications ; Male ; Middle Aged ; Multivariate Analysis ; Recurrence ; Regression Analysis ; Retrospective Studies ; Rifamycins - therapeutic use ; Rifaximin ; rifaximin-α ; United Kingdom</subject><ispartof>Liver international, 2016-09, Vol.36 (9), p.1295-1303</ispartof><rights>2016 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd</rights><rights>2016 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c3981-f855eb6ce88ad67c6c9f9819f9e9d23ebe55a7b14e4119de868a3664846b6e8e3</citedby><cites>FETCH-LOGICAL-c3981-f855eb6ce88ad67c6c9f9819f9e9d23ebe55a7b14e4119de868a3664846b6e8e3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1111%2Fliv.13111$$EPDF$$P50$$Gwiley$$H</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1111%2Fliv.13111$$EHTML$$P50$$Gwiley$$H</linktohtml><link.rule.ids>314,780,784,1417,27924,27925,45574,45575</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/26950766$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Orr, James G.</creatorcontrib><creatorcontrib>Currie, Craig J.</creatorcontrib><creatorcontrib>Berni, Ellen</creatorcontrib><creatorcontrib>Goel, Anurag</creatorcontrib><creatorcontrib>Moriarty, Kieran J.</creatorcontrib><creatorcontrib>Sinha, Ashish</creatorcontrib><creatorcontrib>Gordon, Fiona</creatorcontrib><creatorcontrib>Dethier, Anne</creatorcontrib><creatorcontrib>Dillon, John F.</creatorcontrib><creatorcontrib>Clark, Katie</creatorcontrib><creatorcontrib>Richardson, Paul</creatorcontrib><creatorcontrib>Middleton, Paul</creatorcontrib><creatorcontrib>Patel, Vishal</creatorcontrib><creatorcontrib>Shawcross, Debbie</creatorcontrib><creatorcontrib>Preedy, Helen</creatorcontrib><creatorcontrib>Aspinall, Richard J.</creatorcontrib><creatorcontrib>Hudson, Mark</creatorcontrib><title>The impact on hospital resource utilisation of treatment of hepatic encephalopathy with rifaximin-α</title><title>Liver international</title><addtitle>Liver Int</addtitle><description>Background & Aims
Rifaximin‐α reduces the risk of recurrence of overt hepatic encephalopathy. However, there remain concerns regarding the financial cost of the drug. We aimed to study the impact of treatment with rifaximin‐α on healthcare resource utilisation using data from seven UK liver treatment centres.
Methods
All seven centres agreed a standardised data set and data characterising clinical, demographic and emergency hospital admissions were collected retrospectively for the time periods 3, 6 and 12 months before and following initiation of rifaximin‐α. Admission rates and hospital length of stay before and during therapy were compared. Costs of admissions and drug acquisition were estimated using published sources. Multivariate analyses were carried out to assess the relative impact of various factors on hospital length of stay.
Results
Data were available from 326 patients. Following the commencement of rifaximin, the total hospital length of stay reduced by an estimated 31–53%, equating to a reduction in inpatient costs of between £4858 and £6607 per year. Taking into account drug costs of £3379 for 1‐year treatment with rifaximin‐α, there was an estimated annual mean saving of £1480–£3228 per patient.
Conclusions
Initiation of treatment with rifaximin‐α was associated with a marked reduction in the number of hospital admissions and hospital length of stay. These data suggest that treatment of patients with rifaximin‐α for hepatic encephalopathy was generally cost saving.
See Editorial on Page 1252</description><subject>Aged</subject><subject>cirrhosis</subject><subject>Cost Savings</subject><subject>Drug Costs</subject><subject>Female</subject><subject>Health Care Costs</subject><subject>health economics</subject><subject>Health Resources - statistics & numerical data</subject><subject>hepatic encephalopathy</subject><subject>Hepatic Encephalopathy - drug therapy</subject><subject>Hospitals</subject><subject>Humans</subject><subject>Length of Stay - statistics & numerical data</subject><subject>Liver Cirrhosis - complications</subject><subject>Male</subject><subject>Middle Aged</subject><subject>Multivariate Analysis</subject><subject>Recurrence</subject><subject>Regression Analysis</subject><subject>Retrospective Studies</subject><subject>Rifamycins - therapeutic use</subject><subject>Rifaximin</subject><subject>rifaximin-α</subject><subject>United Kingdom</subject><issn>1478-3223</issn><issn>1478-3231</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2016</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp1kLlOxDAQhi0EYrkKXgC5hCIQx4njlAhxSSvOhS0tx5kohlzYDrCPxYvwTBj26Jhizm_-4kdon4THxMdJrd-PCfXdGtoiccoDGlGyvuojOkLb1r6EIcmyhGyiUcSyJEwZ20LFpAKsm14qh7sWV53ttZM1NmC7wSjAg9O1ttJpf-1K7AxI10DrfocKen9QGFoFfSXrzo_VDH9oV2GjS_mpG90G31-7aKOUtYW9Rd1BTxfnk7OrYHx7eX12Og4UzTgJSp4kkDMFnMuCpYqprPR7nyArIgo5JIlMcxJDTEhWAGdcUsZiHrOcAQe6gw7nur3p3gawTjTaKqhr2UI3WEE4CTljlHCPHs1RZTprDZSiN7qRZiZIKH5NFd5U8WeqZw8WskPeQLEily564GQOfOgaZv8rifH181IymH9o6-Bz9SHNq2ApTRMxvbkUd9P76eNN9CDu6A9JsJK_</recordid><startdate>201609</startdate><enddate>201609</enddate><creator>Orr, James G.</creator><creator>Currie, Craig J.</creator><creator>Berni, Ellen</creator><creator>Goel, Anurag</creator><creator>Moriarty, Kieran J.</creator><creator>Sinha, Ashish</creator><creator>Gordon, Fiona</creator><creator>Dethier, Anne</creator><creator>Dillon, John F.</creator><creator>Clark, Katie</creator><creator>Richardson, Paul</creator><creator>Middleton, Paul</creator><creator>Patel, Vishal</creator><creator>Shawcross, Debbie</creator><creator>Preedy, Helen</creator><creator>Aspinall, Richard J.</creator><creator>Hudson, Mark</creator><general>Blackwell Publishing Ltd</general><scope>BSCLL</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>201609</creationdate><title>The impact on hospital resource utilisation of treatment of hepatic encephalopathy with rifaximin-α</title><author>Orr, James G. ; Currie, Craig J. ; Berni, Ellen ; Goel, Anurag ; Moriarty, Kieran J. ; Sinha, Ashish ; Gordon, Fiona ; Dethier, Anne ; Dillon, John F. ; Clark, Katie ; Richardson, Paul ; Middleton, Paul ; Patel, Vishal ; Shawcross, Debbie ; Preedy, Helen ; Aspinall, Richard J. ; Hudson, Mark</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c3981-f855eb6ce88ad67c6c9f9819f9e9d23ebe55a7b14e4119de868a3664846b6e8e3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2016</creationdate><topic>Aged</topic><topic>cirrhosis</topic><topic>Cost Savings</topic><topic>Drug Costs</topic><topic>Female</topic><topic>Health Care Costs</topic><topic>health economics</topic><topic>Health Resources - statistics & numerical data</topic><topic>hepatic encephalopathy</topic><topic>Hepatic Encephalopathy - drug therapy</topic><topic>Hospitals</topic><topic>Humans</topic><topic>Length of Stay - statistics & numerical data</topic><topic>Liver Cirrhosis - complications</topic><topic>Male</topic><topic>Middle Aged</topic><topic>Multivariate Analysis</topic><topic>Recurrence</topic><topic>Regression Analysis</topic><topic>Retrospective Studies</topic><topic>Rifamycins - therapeutic use</topic><topic>Rifaximin</topic><topic>rifaximin-α</topic><topic>United Kingdom</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Orr, James G.</creatorcontrib><creatorcontrib>Currie, Craig J.</creatorcontrib><creatorcontrib>Berni, Ellen</creatorcontrib><creatorcontrib>Goel, Anurag</creatorcontrib><creatorcontrib>Moriarty, Kieran J.</creatorcontrib><creatorcontrib>Sinha, Ashish</creatorcontrib><creatorcontrib>Gordon, Fiona</creatorcontrib><creatorcontrib>Dethier, Anne</creatorcontrib><creatorcontrib>Dillon, John F.</creatorcontrib><creatorcontrib>Clark, Katie</creatorcontrib><creatorcontrib>Richardson, Paul</creatorcontrib><creatorcontrib>Middleton, Paul</creatorcontrib><creatorcontrib>Patel, Vishal</creatorcontrib><creatorcontrib>Shawcross, Debbie</creatorcontrib><creatorcontrib>Preedy, Helen</creatorcontrib><creatorcontrib>Aspinall, Richard J.</creatorcontrib><creatorcontrib>Hudson, Mark</creatorcontrib><collection>Istex</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Liver international</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Orr, James G.</au><au>Currie, Craig J.</au><au>Berni, Ellen</au><au>Goel, Anurag</au><au>Moriarty, Kieran J.</au><au>Sinha, Ashish</au><au>Gordon, Fiona</au><au>Dethier, Anne</au><au>Dillon, John F.</au><au>Clark, Katie</au><au>Richardson, Paul</au><au>Middleton, Paul</au><au>Patel, Vishal</au><au>Shawcross, Debbie</au><au>Preedy, Helen</au><au>Aspinall, Richard J.</au><au>Hudson, Mark</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>The impact on hospital resource utilisation of treatment of hepatic encephalopathy with rifaximin-α</atitle><jtitle>Liver international</jtitle><addtitle>Liver Int</addtitle><date>2016-09</date><risdate>2016</risdate><volume>36</volume><issue>9</issue><spage>1295</spage><epage>1303</epage><pages>1295-1303</pages><issn>1478-3223</issn><eissn>1478-3231</eissn><abstract>Background & Aims
Rifaximin‐α reduces the risk of recurrence of overt hepatic encephalopathy. However, there remain concerns regarding the financial cost of the drug. We aimed to study the impact of treatment with rifaximin‐α on healthcare resource utilisation using data from seven UK liver treatment centres.
Methods
All seven centres agreed a standardised data set and data characterising clinical, demographic and emergency hospital admissions were collected retrospectively for the time periods 3, 6 and 12 months before and following initiation of rifaximin‐α. Admission rates and hospital length of stay before and during therapy were compared. Costs of admissions and drug acquisition were estimated using published sources. Multivariate analyses were carried out to assess the relative impact of various factors on hospital length of stay.
Results
Data were available from 326 patients. Following the commencement of rifaximin, the total hospital length of stay reduced by an estimated 31–53%, equating to a reduction in inpatient costs of between £4858 and £6607 per year. Taking into account drug costs of £3379 for 1‐year treatment with rifaximin‐α, there was an estimated annual mean saving of £1480–£3228 per patient.
Conclusions
Initiation of treatment with rifaximin‐α was associated with a marked reduction in the number of hospital admissions and hospital length of stay. These data suggest that treatment of patients with rifaximin‐α for hepatic encephalopathy was generally cost saving.
See Editorial on Page 1252</abstract><cop>United States</cop><pub>Blackwell Publishing Ltd</pub><pmid>26950766</pmid><doi>10.1111/liv.13111</doi><tpages>9</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1478-3223 |
| ispartof | Liver international, 2016-09, Vol.36 (9), p.1295-1303 |
| issn | 1478-3223 1478-3231 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_1810866318 |
| source | MEDLINE; Wiley Journals |
| subjects | Aged cirrhosis Cost Savings Drug Costs Female Health Care Costs health economics Health Resources - statistics & numerical data hepatic encephalopathy Hepatic Encephalopathy - drug therapy Hospitals Humans Length of Stay - statistics & numerical data Liver Cirrhosis - complications Male Middle Aged Multivariate Analysis Recurrence Regression Analysis Retrospective Studies Rifamycins - therapeutic use Rifaximin rifaximin-α United Kingdom |
| title | The impact on hospital resource utilisation of treatment of hepatic encephalopathy with rifaximin-α |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-05T07%3A39%3A08IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=The%20impact%20on%20hospital%20resource%20utilisation%20of%20treatment%20of%20hepatic%20encephalopathy%20with%20rifaximin-%CE%B1&rft.jtitle=Liver%20international&rft.au=Orr,%20James%20G.&rft.date=2016-09&rft.volume=36&rft.issue=9&rft.spage=1295&rft.epage=1303&rft.pages=1295-1303&rft.issn=1478-3223&rft.eissn=1478-3231&rft_id=info:doi/10.1111/liv.13111&rft_dat=%3Cproquest_cross%3E1810866318%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1810866318&rft_id=info:pmid/26950766&rfr_iscdi=true |